RENA LINDEN: Open Payments
NPI 1265081780 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,186 in 103 payments from 13 companies in 2025. Trend: 2023 $1,600 · 2024 $1,541 · 2025 $2,186
Food & beverage: $2,186
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 18 | $367 |
| Teva Pharmaceuticals USA, Inc. | 18 | $343 |
| ABBVIE INC. | 22 | $340 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $281 |
| Neurocrine BioSciences, Inc. | 8 | $212 |
| Janssen Pharmaceuticals, Inc | 6 | $194 |
| Otsuka America Pharmaceutical, Inc. | 7 | $167 |
| E.R. Squibb & Sons, L.L.C. | 5 | $114 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
| Lundbeck LLC | 1 | $29 |
Products named: VRAYLAR, CAPLYTA, ARISTADA, INGREZZA, INVEGA SUSTENNA, AUSTEDO XR, UZEDY, LYBALVI.
Industry payments across PA — which companies pay providers there.
